By Iain Gilbert
Date: Tuesday 03 Apr 2018
LONDON (ShareCast) - (ShareCast News) - Molecular diagnostics company Genedrive is set to premiere its qualitative hep-C assay at a major Asia Pacific exhibition in Singapore this week.
Having recently made first commercial sales of instruments and assays to Sysmex across the European, Middle Eastern and African markets, Genedrive inked a deal with Sysmex's Asia Pacific subsidiary to cover the Asia Pacific region, excluding India.
Genedrive's qualitative hepatitis C assay, HCV ID, provides results within 90 minutes within a decentralised testing environment. The HCD is performed on the company's portable molecular diagnostics platform, created to support the roll-out of direct-acting antivirals in low and middle-income countries.
Separately, Genedrive's HCV ID kit's first external validation study, conducted in South Africa, returned 100% specificity and sensitivity in independent use, confirming that its "good clinical validation performance can be translated into real-world settings".
As of 0845 BST, shares had declined 2.47% to 39.50p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 1.83p |
Change Today | -0.17p |
% Change | -8.66 % |
52 Week High | 22.25 |
52 Week Low | 1.80 |
Volume | 3,823,893 |
Shares Issued | 154.32m |
Market Cap | £2.82m |
RiskGrade | 747 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
17:07 | 10,000 @ 1.83p |
16:25 | 125,000 @ 1.81p |
16:17 | 20,999 @ 1.81p |
15:59 | 10,198 @ 1.84p |
15:02 | 235 @ 1.84p |
You are here: research